BrightSpring Health Services, Inc.
For the period ended Sep 30, 2025. Filed Oct 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Loss · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at June 30, 2025 | 177,055,327 | $1,771 | $1,909,854 | $(164,405) | $(4,330) | $(283) | $1,742,607 |
| Net income (1) | — | — | — | 55,836 | — | 377 | 56,213 |
| Other comprehensive loss, net of tax | — | — | — | — | (1,961) | — | (1,961) |
| Share-based compensation | — | — | 17,250 | — | — | — | 17,250 |
| Exercise of stock options | 735,483 | 7 | 5,612 | — | — | — | 5,619 |
| Issuance of common stock for settlement of RSUs | 115,810 | 1 | (1) | — | — | — | — |
| Tax effect of net share settlement of equity awards | (52,203) | — | (1,071) | — | — | — | (1,071) |
| Conversion of tangible equity units into common stock | 2,831,467 | 28 | (28) | — | — | — | — |
| Balances at September 30, 2025 | 180,685,884 | $1,807 | $1,931,616 | $(108,569) | $(6,291) | $94 | $1,818,657 |
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at June 30, 2024 | 171,397,030 | $1,714 | $1,804,965 | $(226,150) | $19,025 | $379 | $1,599,933 |
| Net loss (1) | — | — | — | (8,230) | — | (178) | (8,408) |
| Other comprehensive loss, net of tax | — | — | — | — | (19,730) | — | (19,730) |
| Share-based compensation | — | — | 15,210 | — | — | — | 15,210 |
| Shares issued under share-based compensation plan, including tax effects | 210,696 | 2 | 507 | — | — | — | 509 |
| Shares issued for payment of acquisition | 2,471,251 | 25 | 29,975 | — | — | — | 30,000 |
| Derecognition of redeemable noncontrolling interest | — | — | (2,542) | — | — | — | (2,542) |
| Balances at September 30, 2024 | 174,078,977 | $1,741 | $1,848,115 | $(234,380) | $(705) | $201 | $1,614,972 |
(1) Net income (loss) to the Company for the three months ended September 30, 2025 and 2024 excludes$(455) and$(573), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
Condensed Consolidated Statements of Shareholders’ Equity (continued)
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2024 | 174,245,990 | $1,742 | $1,866,850 | $(222,155) | $1,418 | $— | $1,647,855 |
| Net income (1) | — | — | — | 113,586 | — | 94 | 113,680 |
| Other comprehensive loss, net of tax | — | — | — | — | (7,709) | — | (7,709) |
| Share-based compensation | — | — | 55,733 | — | — | — | 55,733 |
| Exercise of stock options | 2,055,618 | 21 | 14,660 | — | — | — | 14,681 |
| Issuance of common stock for settlement of RSUs | 1,817,356 | 18 | (18) | — | — | — | — |
| Tax effect of net share settlement of equity awards | (264,547) | (2) | (5,581) | — | — | — | (5,583) |
| Conversion of tangible equity units into common stock | 2,831,467 | 28 | (28) | — | — | — | — |
| Balances at September 30, 2025 | 180,685,884 | $1,807 | $1,931,616 | $(108,569) | $(6,291) | $94 | $1,818,657 |
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2023 | 117,857,055 | $1,179 | $771,336 | $(200,319) | $12,544 | $670 | $585,410 |
| Net loss (1) | — | — | — | (34,061) | — | (469) | (34,530) |
| Other comprehensive loss, net of tax | — | — | — | — | (13,249) | — | (13,249) |
| Share-based compensation | — | — | 55,194 | — | — | — | 55,194 |
| Shares issued under share-based compensation plan, including tax effects | 318,085 | 3 | 528 | — | — | — | 531 |
| Shares issued for payment of acquisition | 2,570,503 | 26 | 31,055 | — | — | — | 31,081 |
| Derecognition of redeemable noncontrolling interest | — | — | 12,439 | — | — | — | 12,439 |
| Issuance of common stock on initial public offering, net (2) | 53,333,334 | 533 | 655,952 | — | — | — | 656,485 |
| Proceeds from stock purchase contract issued under tangible equity units, net (3) | — | — | 321,611 | — | — | — | 321,611 |
| Balances at September 30, 2024 | 174,078,977 | $1,741 | $1,848,115 | $(234,380) | $(705) | $201 | $1,614,972 |
(1) Net income (loss) to the Company for the nine months ended September 30, 2025 and 2024 excludes$(1,370) and$(1,395), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
(2)Issuance of common stock on initial public offering is presented net of underwriting discounts and commissions, and offering-related expenses of $36.8 million.
(3) Proceeds from stock purchase contract issued under tangible equity units is presented net of underwriting discounts and commissions of $9.1 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.